期刊文献+

影响抗血管内皮生成因子治疗渗出型老年性黄斑变性预后的因素 被引量:2

原文传递
导出
摘要 玻璃体腔注射抗血管内皮生长因子(VEGF)药物是治疗渗出型老年性黄斑变性(AMD)脉络膜新生血管(CNV)的安全有效方法。但基线视力、年龄、首发症状、开始治疗的时间、对最初3次治疗的反应以及光相干断层扫描、荧光索眼底血管造影、眼底自身荧光检查结果不同的患者,其治疗预后差异较大;除了上述临床特征和指标外,基因及生物学标记物方面的差异对治疗预后也有影响。探讨影响渗出型AMD患者抗VEGF治疗预后众多相关因素中的主要因素并采取相应的对策,对于提升抗VEGF药物治疗效果具有积极意义。
作者 张笑哲 常青
出处 《中华眼底病杂志》 CAS CSCD 北大核心 2013年第4期435-438,共4页 Chinese Journal of Ocular Fundus Diseases
  • 相关文献

参考文献48

  • 1Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age related macular degeneration. Ophthalmology, 2008,115 : 116-126.
  • 2Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a muhicenter cohort study (SEVEN-UP)[J/OL]. Ophthalmology, 2013, 120: E1 [2013-05-03]. http//www. sciencedirect, com/science/ar ticle/pii/S016164201300331 X#.
  • 3CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age related macular degeneration. New EngJ Med, 2011,364:1897-1908.
  • 4Rasmussen A, Bloch SB, Fuchs J, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration [ J/OL]. Ophthalmology, 2013, 120: El [ 2013-07-08 ]. http://www, sciencedirect, com/ science/ article/pii /S0161642013004442.
  • 5Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovaseular age-related rnaeular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol, 2007, 144: 850-857.
  • 6Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related maeular degeneration. Ophthalmology, 2007,114 : 246-252.
  • 7Heimes B, Lommatzsch A, Zeimer M, et al. Anti-VEGF therapy of exudative AMD: prognostic factors for therapy success. Ophthalmologe, 2011,108 : 124-131.
  • 8Tran TH, Querques G, Forzy G, et al. Angiographic regression patterns after intravitreal ranibizumab injections for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging, 2011,42 : 498-508.
  • 9McKibbin M, All M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovaseularage-related maeular degeneration. Br J Ophthalmol, 2012,96:208-212.
  • 10Kim YM, Kim JH, Koh HJ. Improvement of photoreeeptor integrity and associated visual outcome in neovaseular age-related macular degeneration. Am J Ophthalmol, 2012,154: 164-173.

同被引文献28

  • 1邹海东,柏林,刘海芸,张皙.老年性黄斑变性对生存质量的影响[J].中华眼底病杂志,2004,20(5):303-306. 被引量:25
  • 2邹海东,张晳,许迅,汪枫桦,张世杰.上海市静安区曹家渡街道年龄相关性黄斑变性的患病率调查[J].中华眼科杂志,2005,4(1):15-19. 被引量:107
  • 3崔红培,周尚昆,毛海燕.益气复明汤治疗湿性脾气虚弱型老年性黄斑变性37例观察[J].四川中医,2006,24(2):94-95. 被引量:12
  • 4Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis[J]. BMC Ophthalmol, 2010, 10: 31.
  • 5Nigam N, Hedaya J, Freeman WR. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions[J]. Br J Ophthalmol, 2008, 92(6): 864-865.
  • 6Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials[J]. Ophthalmology, 2011, 118(3): 523-530.
  • 7Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age- related macular degeneration[J]. Am J Ophthalmol, 2013, 156 (1): 29-35.
  • 8Shin JY, Woo S J, Ahn J, et al. Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography[J]. Korean J Ophthalmol, 2013, 27(6): 425-432.
  • 9Arcinue CA, Ma F, Barteselli G, et al. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration[J]. Am J Ophthalmol, 2015, 159(3): 426-436.
  • 10Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age- related macular degeneration[J]. Am J Ophthalmol, 2007, 143 (4): 566-583.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部